Terry O’Reilly
Celerion (United States)(US)Sunesis (United States)(US)
Publications by Year
Research Areas
Liver Disease Diagnosis and Treatment, Hepatitis C virus research, PI3K/AKT/mTOR signaling in cancer, Chronic Myeloid Leukemia Treatments, Diverticular Disease and Complications
Most-Cited Works
- → Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts(2004)161 cited
- → Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK(2015)73 cited
- → Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo(2010)67 cited
- → First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers(2019)61 cited
- → Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials(2020)52 cited
- → Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma